Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naıve healthy volunteers

3,4-Methylenedioxymethamphetamine (MDMA, “ecstasy”) is a phenylethylamine with structural similarities to both amphetamine and mescaline that recreational users and some investigators have described as producing an ‘‘entactogenic’’ state characterised by enhanced emotional openness and well‑being. Animal studies have shown that repeated or high doses of MDMA can produce long‑term serotonergic changes, but the relevance of those findings to single recreational doses in humans is unresolved. Earlier human investigations have reported peaceful, empathic subjective effects and signs of sympathetic arousal, but most prior work relied on experienced users or non‑controlled contexts, leaving open the phenomenology of MDMA in MDMA‑naïve volunteers and its acute cognitive and cardiovascular effects. This double‑blind, placebo‑controlled study by Vollenweider and colleagues set out to characterise the acute psychological, cognitive and cardiovascular effects of a single typical recreational oral dose of MDMA (1.7 mg/kg) in 13 MDMA‑naïve healthy volunteers. The investigators also assessed short‑term somatic aftereffects up to 24 hours after ingestion and tested selective attention with a trial‑by‑trial Stroop colour‑naming task to examine whether MDMA produces measurable attentional deficits.

The study used a randomised double‑blind placebo‑controlled crossover design. Thirteen healthy volunteers (10 men, 3 women; age range 23–47 years; mean 29 ± 7) recruited from university and hospital staff completed two sessions at monthly intervals, receiving either MDMA (1.7 mg/kg PO) or placebo in counterbalanced order. Subjects were screened to exclude personal or first‑degree family histories of major psychiatric disorder and prior illicit drug abuse; extreme scores on selected personality dimensions were additional exclusion criteria but did not necessitate exclusions in this sample. Ethical approval and regulatory authorisation for MDMA use were obtained. Baseline assessments included the Adjective Mood Rating Scale (EWL) and a modified Altered States of Consciousness questionnaire (APZ‑OAV). Drug or placebo was administered about 13:30; peak‑effect psychometric ratings were obtained 75 minutes after ingestion (and within a 75–120 minute window). Physiological measurements (blood pressure, pulse and body temperature) were taken at 0, 75, 150 and 300 minutes post ingestion. Acute adverse effects were monitored with a vegetative lability scale over the 0–360 minute session and were reassessed for sequelae at 24 hours. Cognitive testing at the anticipated peak effect included a trial‑by‑trial computerized Stroop colour‑naming task (192 trials across congruent, conflict, control X and control W conditions) to probe selective attention and central inhibitory processes, and a prepulse inhibition (PPI) of acoustic startle protocol; the PPI analyses were ongoing and reported separately. Psychometric instruments were described in detail: the EWL yields subscales for efficiency, inactivation, extraversion/introversion, well‑being (with self‑confidence and heightened mood subscales), emotional excitability and state anxiety; the APZ‑OAV yields three dimensions—oceanic boundlessness (OSE), visionary restructuralization (VUS) and dread of ego dissolution (AIA)—with several item clusters each. Statistical analysis treated each subject as their own control. Repeated‑measures two‑way ANOVAs were used to examine drug (placebo vs MDMA) by time or condition effects for psychometric scores, vital signs and Stroop performance; significant main effects or interactions were followed by LSD post hoc tests. Probability values ≤ .05 were considered statistically significant.

Psychological effects: During the peak effects (75–120 minutes post ingestion), MDMA produced robust positive affective changes on the EWL mood scale. Repeated‑measures analysis indicated a significant interaction of MDMA with EWL subscales; post hoc tests showed increased extraversion/introversion, well‑being (including self‑confidence and heightened mood), and emotional excitability (all statistically significant), and an increase in the overall state anxiety score driven specifically by the ‘‘thoughtfulness–contemplativeness’’ subscale rather than by apprehension or dejection. Subjects reported heightened responsiveness to emotions, increased openness and a desire to communicate, while a minority became inward‑focused. On the APZ‑OAV, MDMA produced a distinctive profile: significant increases were seen in all three dimensions (OSE, VUS and AIA) but with a pattern of relatively high OSE (oceanic boundlessness) and more modest VUS and AIA elevations. Within OSE, significant increases occurred for derealization, depersonalization, alterations in the sense of space and time and mania‑like experience, with the largest change in the positive basic mood cluster. In VUS, scores rose for changed meaning of percepts, illusions, facilitated recollection and imagination, whereas hallucinations and synesthesias were not significantly altered. For AIA, increases were significant for thought disorder and loss of body control; frightening derealization, delusion and loss of thought control were not increased. Cognitive testing (Stroop): MDMA had no significant effect on Stroop reaction times or error rates compared with placebo. The expected Stroop condition effects (differences among congruent, conflict, control trials) were observed, but there were no significant main effects of drug nor drug×condition interactions. Interference and facilitation measures did not differ between MDMA and placebo, indicating no detectable impairment of selective attention in this paradigm at the dose tested. Vital signs: MDMA produced moderate, transient increases in systolic and diastolic blood pressure, peaking roughly 2 hours after administration. Reported increases were on the order of 10–30 mm Hg for systolic and 5–10 mm Hg for diastolic pressure. Twelve of 13 subjects reached a typical peak near 160/100 mm Hg; one 49‑year‑old subject exhibited a transient extreme hypertensive response (reported peak 240/145 mm Hg) lasting about 20 minutes without pharmacological intervention. Pulse rate was elevated in all subjects but not analysed in detail. Body temperature showed a small non‑significant rise (approximately 0.2–0.5 °C). Acute adverse effects and 24‑hour sequelae: No unexpected severe complications or persisting psychosis were observed. The most frequent acute somatic complaints (8/13) were jaw clenching (bruxism), lack of appetite, impaired gait/disturbance of balance and difficulty concentrating. Other acute symptoms included restless or heavy legs, paresthesias, altered temperature sensitivity, palpitations, sweating and thirst. Several effects persisted into the next day in some subjects: suppressed appetite and thirst (6/13), jaw clenching (4/13), restlessness (5/13), difficulty concentrating (4/13) and sweating (3/13). Newly reported 24‑hour aftereffects included lack of energy (6/13), insomnia (5/13) and brooding (3/13). Overall, roughly one‑third of subjects reported some lingering adverse symptoms at 24 hours.

Vollenweider and colleagues interpret their findings as evidence that a single moderate recreational dose of MDMA in MDMA‑naïve healthy volunteers produces a characteristic affective state of enhanced mood, well‑being and emotional sensitivity, accompanied by moderate perceptual alterations (derealization/depersonalization) and mild thought disorder, but without frank hallucinations, panic reactions or marked psychomotor stimulation. The increased score on the EWL ‘‘thoughtfulness–contemplativeness’’ items is taken to reflect inward‑turning, contemplative states rather than clinical anxiety; nonetheless, the investigators acknowledge that initial signs of loss of body control produced transient concern in some participants and that, in uncontrolled settings or at higher doses, anxiety or panic could occur. The APZ‑OAV profile observed—high oceanic boundlessness with relatively low visionary restructuralization and dread of ego dissolution—led the authors to emphasise that MDMA’s subjective profile differs from classic hallucinogens such as psilocybin and from stimulants such as d‑amphetamine. A direct comparison cited by the authors indicated OSE scores for MDMA approximating those after psilocybin but with substantially lower VUS and AIA scores; MDMA produced sensory intensification and visual illusions rather than true hallucinations. Cognitive results are consistent with this distinction: unlike psilocybin in prior work, MDMA did not impair Stroop performance, suggesting selective attention was preserved in this brief task despite reported thought disturbance and difficulties in concentration on longer or more demanding tasks. Cardiovascular and somatic safety considerations received prominent attention. The study found moderate increases in blood pressure in most subjects and documented a transient severe hypertensive event in one volunteer. The authors stress that even recreational doses can provoke substantial blood pressure elevations and that such effects could be clinically important in individuals with latent cardiovascular vulnerability or when higher/repeated doses are taken in hot, physically strenuous settings such as raves, where hyperthermia and dehydration may magnify risk. Although a small, non‑significant body‑temperature rise was observed at rest, animal data and case reports suggest hyperthermia is dose‑ and context‑dependent. Regarding aftereffects, the investigators note that some somatic and cognitive complaints persisted up to 24 hours in a subset of subjects and suggest that interindividual differences in MDMA metabolism or active metabolites could underlie these sequelae. They also reiterate that while a single moderate dose is unlikely to produce long‑term serotonergic deficits in humans, animal data indicate that repeated or high dosing could cause lasting serotonergic changes, and therefore repeated human use may carry greater risk. Finally, the authors argue that careful screening, controlled dosing and clinical setting likely reduce psychiatric complications seen in uncontrolled recreational use, but they caution that personality traits, set and setting, dose and substance purity remain important determinants of individual responses. The authors acknowledge that some analyses (prepulse inhibition) were not yet reported and that comparisons across drugs and doses would benefit from dose–response studies to confirm the distinctions suggested by their data.